{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T16:11:28Z","timestamp":1775837488989,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T00:00:00Z","timestamp":1532649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Parents\u2019 Initiative Group for Children with Leukemia- and Solid Tumors W\u00fcrzburg e.V."},{"name":"Tour of Hope Foundation e.V."},{"name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung Wuerzburg","award":["B-107"],"award-info":[{"award-number":["B-107"]}]},{"name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung Wuerzburg","award":["B-107"],"award-info":[{"award-number":["B-107"]}]},{"name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung Wuerzburg","award":["B-107"],"award-info":[{"award-number":["B-107"]}]},{"DOI":"10.13039\/501100007311","name":"Deutsche Kinderkrebsstiftung","doi-asserted-by":"crossref","award":["DKKS 2015.15"],"award-info":[{"award-number":["DKKS 2015.15"]}],"id":[{"id":"10.13039\/501100007311","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Vogel-Stiftung Dr. Eckernkamp"},{"name":"Promotionsstipendium der Medizinischen Fakult\u00e4t"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00262-018-2214-0","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T06:47:20Z","timestamp":1532674040000},"page":"1545-1558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with Treg depletion"],"prefix":"10.1007","volume":"67","author":[{"given":"Mario","family":"L\u00f6hr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Technau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camelia-Maria","family":"Monoranu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Rachor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred B.","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Hagemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almuth F.","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Linsenmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"W\u00f6lfl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf-Ingo","family":"Ernestus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6tz","family":"Gelbrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G.","family":"Schlegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Eyrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,27]]},"reference":[{"key":"2214_CR1","doi-asserted-by":"crossref","unstructured":"Eyrich M, Krauss J, L\u00f6hr M, Technau A, Rachor J, Monoranu CM, Warmuth-Metz M, W\u00f6lfl M, Kramm C, Schlegel P (2016) Dendritic cell vaccination with partial Treg depletion in relapsed glioblastoma\u2014results from the pilot phase of the HIT-HGG Rez Immunvac study. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16\u201319, 2015; New York, NY. (Philadelphia (PA): AACR; Cancer Immunol Res 4(1 Suppl):Abstract nr A045)","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR15-A045"},{"key":"2214_CR2","first-page":"361","volume":"229","author":"A Technau","year":"2017","unstructured":"Technau A, Freitag B, L\u00f6hr M, Hagemann C, Rachor J, Keupp A, Stein U, Monoranu C, Ke\u00dfler A, Krau\u00df J, W\u00f6lfl M, Ernestus RI, Gierlich P, Engelhardt S, Gelbrich G, Schlegel PG, Eyrich M (2017) High-grade glioma associated immunosuppression does not prevent immune responses induced by vaccination with autologous, tumor-lysate pulsed dendritic cells. Klin Padiatr 229: 361\u2013366. (Oral presentation nr 8)","journal-title":"Klin Padiatr"},{"key":"2214_CR3","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1084\/jem.136.6.1631","volume":"136","author":"WH Brooks","year":"1972","unstructured":"Brooks WH, Netsky MG, Normansell DE, Horwitz DA (1972) Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med 136:1631\u20131647","journal-title":"J Exp Med"},{"key":"2214_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3171\/jns.2006.105.1.41","volume":"105","author":"M Rapp","year":"2006","unstructured":"Rapp M, Ozcan Z, Steiger HJ, Wernet P, Sabel MC, Sorg RV (2006) Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy. J Neurosurg 105:41\u201350","journal-title":"J Neurosurg"},{"key":"2214_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/neuonc\/noq001","volume":"12","author":"MP Gustafson","year":"2010","unstructured":"Gustafson MP, Lin Y, New KC, Bulur PA, O\u2019Neill BP, Gastineau DA, Dietz AB (2010) Systemic immune suppression in glioblastoma: the interplay between CD14+ HLA-DRlo\/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol 12:631\u2013644","journal-title":"Neuro Oncol"},{"key":"2214_CR6","doi-asserted-by":"publisher","first-page":"6562","DOI":"10.4049\/jimmunol.0803831","volume":"182","author":"S Mandruzzato","year":"2009","unstructured":"Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, Zanon A, Rossi CR, Nitti D, Bronte V, Zanovello P (2009) IL4Ralpha + myeloid-derived suppressor cell expansion in cancer patients. J Immunol 182:6562\u20136568","journal-title":"J Immunol"},{"key":"2214_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/neuonc\/nop023","volume":"12","author":"JC Rodrigues","year":"2010","unstructured":"Rodrigues JC, Gonzalez GC, Zhang L, Ibrahim G, Kelly JJ, Gustafson MP, Lin Y, Dietz AB, Forsyth PA, Yong VW, Parney IF (2010) Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol 12:351\u2013365","journal-title":"Neuro Oncol"},{"key":"2214_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11060-013-1171-x","volume":"114","author":"Y Lin","year":"2013","unstructured":"Lin Y, Zhang G, Zhang J, Gao G, Li M, Chen Y, Wang J, Li G, Song SW, Qiu X, Wang Y, Jiang T (2013) A panel of four cytokines predicts the prognosis of patients with malignant gliomas. J Neurooncol 114:199\u2013208","journal-title":"J Neurooncol"},{"key":"2214_CR9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/neuonc\/nor042","volume":"13","author":"B Raychaudhuri","year":"2011","unstructured":"Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, Garcia J, Vogelbaum MA, Finke J (2011) Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 13:591\u2013599","journal-title":"Neuro Oncol"},{"key":"2214_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11060-005-9116-7","volume":"79","author":"T Schneider","year":"2006","unstructured":"Schneider T, Sailer M, Ansorge S, Firsching R, Reinhold D (2006) Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma. J Neurooncol 79:61\u201365","journal-title":"J Neurooncol"},{"key":"2214_CR11","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1158\/0008-5472.CAN-10-3055","volume":"71","author":"M Fujita","year":"2011","unstructured":"Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, Ohlfest JR, Okada H (2011) COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res 71:2664\u20132674","journal-title":"Cancer Res"},{"key":"2214_CR12","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/ijc.23284","volume":"122","author":"OM Grauer","year":"2008","unstructured":"Grauer OM, Sutmuller RP, van Maren W, Jacobs JF, Bennink E, Toonen LW, Nierkens S, Adema GJ (2008) Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int J Cancer 122:1794\u20131802","journal-title":"Int J Cancer"},{"key":"2214_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1215\/15228517-2009-004","volume":"11","author":"W Maes","year":"2009","unstructured":"Maes W, Rosas GG, Verbinnen B, Boon L, De Vleeschouwer S, Ceuppens JL, Van Gool SW (2009) DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol 11:529\u2013542","journal-title":"Neuro Oncol"},{"key":"2214_CR14","doi-asserted-by":"publisher","first-page":"5955","DOI":"10.1158\/0008-5472.CAN-07-5973","volume":"68","author":"CJ Wheeler","year":"2008","unstructured":"Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S, Goldfinger D, Ng H, Irvin D, Yu JS (2008) Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68:5955\u20135964","journal-title":"Cancer Res"},{"key":"2214_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1186\/1471-2407-12-623","volume":"12","author":"Y Akiyama","year":"2012","unstructured":"Akiyama Y, Oshita C, Kume A, Iizuka A, Miyata H, Komiyama M, Ashizawa T, Yagoto M, Abe Y, Mitsuya K, Watanabe R, Sugino T, Yamaguchi K, Nakasu Y (2012) alpha-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial. BMC Cancer 12:623","journal-title":"BMC Cancer"},{"key":"2214_CR16","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.1158\/1078-0432.CCR-05-0464","volume":"11","author":"LM Liau","year":"2005","unstructured":"Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11:5515\u20135525","journal-title":"Clin Cancer Res"},{"key":"2214_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00262-012-1319-0","volume":"62","author":"S Phuphanich","year":"2013","unstructured":"Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuno MA, Richardson JE, Fan X, Ji J, Chu RM, Bender JG, Hawkins ES, Patil CG, Black KL, Yu JS (2013) Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 62:125\u2013135","journal-title":"Cancer Immunol Immunother"},{"key":"2214_CR18","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/sj.bjc.6601268","volume":"89","author":"R Yamanaka","year":"2003","unstructured":"Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T, Narita M, Takahashi M, Tanaka R (2003) Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I\/II trial. Br J Cancer 89:1172\u20131179","journal-title":"Br J Cancer"},{"key":"2214_CR19","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-05-0120","volume":"11","author":"R Yamanaka","year":"2005","unstructured":"Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, Yoshida S, Abe T, Narita M, Takahashi M, Tanaka R (2005) Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I\/II trial. Clin Cancer Res 11:4160\u20134167","journal-title":"Clin Cancer Res"},{"key":"2214_CR20","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1158\/0008-5472.CAN-03-3505","volume":"64","author":"JS Yu","year":"2004","unstructured":"Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973\u20134979","journal-title":"Cancer Res"},{"key":"2214_CR21","first-page":"842","volume":"61","author":"JS Yu","year":"2001","unstructured":"Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM, Black KL (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842\u2013847","journal-title":"Cancer Res"},{"key":"2214_CR22","first-page":"1649","volume":"49","author":"M Awwad","year":"1989","unstructured":"Awwad M, North RJ (1989) Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res 49:1649\u20131654","journal-title":"Cancer Res"},{"key":"2214_CR23","doi-asserted-by":"publisher","first-page":"e1005521","DOI":"10.1080\/2162402X.2015.1005521","volume":"4","author":"J Wu","year":"2015","unstructured":"Wu J, Waxman DJ (2015) Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor CD8+ T-cell responses and immune memory. Oncoimmunology 4:e1005521","journal-title":"Oncoimmunology"},{"key":"2214_CR24","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/nm.2883","volume":"18","author":"S Walter","year":"2012","unstructured":"Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18:1254\u20131261","journal-title":"Nat Med"},{"key":"2214_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00262-011-1106-3","volume":"61","author":"Y Ge","year":"2012","unstructured":"Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, Blumenstein M, Thum J, Sohn C, Schneeweiss A, Beckhove P, Schuetz F (2012) Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 61:353\u2013362","journal-title":"Cancer Immunol Immunother"},{"key":"2214_CR26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","volume":"56","author":"F Ghiringhelli","year":"2007","unstructured":"Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641\u2013648","journal-title":"Cancer Immunol Immunother"},{"key":"2214_CR27","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jcyt.2014.02.017","volume":"16","author":"M Eyrich","year":"2014","unstructured":"Eyrich M, Schreiber SC, Rachor J, Krauss J, Pauwels F, Hain J, Wolfl M, Lutz MB, de Vleeschouwer S, Schlegel PG, Van Gool SW (2014) Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells. Cytotherapy 16:946\u2013964","journal-title":"Cytotherapy"},{"key":"2214_CR28","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.2006.08.5829","volume":"25","author":"P Filipazzi","year":"2007","unstructured":"Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25:2546\u20132553","journal-title":"J Clin Oncol"},{"key":"2214_CR29","doi-asserted-by":"publisher","first-page":"8270","DOI":"10.1158\/1078-0432.CCR-08-0165","volume":"14","author":"S Kusmartsev","year":"2008","unstructured":"Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H, Yancey D, Dahm P, Vieweg J (2008) Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 14:8270\u20138278","journal-title":"Clin Cancer Res"},{"key":"2214_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1189\/jlb.0310162","volume":"89","author":"S Brandau","year":"2011","unstructured":"Brandau S, Trellakis S, Bruderek K, Schmaltz D, Steller G, Elian M, Suttmann H, Schenck M, Welling J, Zabel P, Lang S (2011) Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol 89:311\u2013317","journal-title":"J Leukoc Biol"},{"key":"2214_CR31","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/0008-5472.CAN-08-1921","volume":"69","author":"PC Rodriguez","year":"2009","unstructured":"Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC (2009) Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69:1553\u20131560","journal-title":"Cancer Res"},{"key":"2214_CR32","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.4049\/jimmunol.163.12.6867","volume":"163","author":"US Kammula","year":"1999","unstructured":"Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA, Marincola FM (1999) Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol 163:6867\u20136875","journal-title":"J Immunol"},{"key":"2214_CR33","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1172\/JCI41911","volume":"120","author":"EH Wilson","year":"2010","unstructured":"Wilson EH, Weninger W, Hunter CA (2010) Trafficking of immune cells in the central nervous system. J Clin Invest 120:1368\u20131379","journal-title":"J Clin Invest"},{"issue":"Suppl 7","key":"2214_CR34","doi-asserted-by":"publisher","first-page":"vii9","DOI":"10.1093\/neuonc\/nov151","volume":"17","author":"EK Nduom","year":"2015","unstructured":"Nduom EK, Weller M, Heimberger AB (2015) Immunosuppressive mechanisms in glioblastoma. Neuro Oncol 17(Suppl 7):vii9\u2013vii14","journal-title":"Neuro Oncol"},{"key":"2214_CR35","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/jcb.21473","volume":"102","author":"L Vujanovic","year":"2007","unstructured":"Vujanovic L, Butterfield LH (2007) Melanoma cancer vaccines and anti-tumor T cell responses. J Cell Biochem 102:301\u2013310","journal-title":"J Cell Biochem"},{"key":"2214_CR36","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0165-5728(99)00203-9","volume":"100","author":"AR Dix","year":"1999","unstructured":"Dix AR, Brooks WH, Roszman TL, Morford LA (1999) Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 100:216\u2013232","journal-title":"J Neuroimmunol"},{"key":"2214_CR37","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1158\/1078-0432.CCR-06-2070","volume":"13","author":"PE Fecci","year":"2007","unstructured":"Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH (2007) Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13:2158\u20132167","journal-title":"Clin Cancer Res"},{"key":"2214_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4103\/2152-7806.134104","volume":"5","author":"K Gousias","year":"2014","unstructured":"Gousias K, Voulgaris S, Vartholomatos G, Voulgari P, Kyritsis AP, Markou M (2014) Prognostic value of the preoperative immunological profile in patients with glioblastoma. Surg Neurol Int 5:89","journal-title":"Surg Neurol Int"},{"key":"2214_CR39","doi-asserted-by":"publisher","first-page":"979748","DOI":"10.1155\/2013\/979748","volume":"2013","author":"R Albulescu","year":"2013","unstructured":"Albulescu R, Codrici E, Popescu ID, Mihai S, Necula LG, Petrescu D, Teodoru M, Tanase CP (2013) Cytokine patterns in brain tumour progression. Mediators Inflamm 2013:979748","journal-title":"Mediators Inflamm"},{"key":"2214_CR40","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1186\/s12885-015-1629-7","volume":"15","author":"S Han","year":"2015","unstructured":"Han S, Liu Y, Li Q, Li Z, Hou H, Wu A (2015) Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma. BMC Cancer 15:617","journal-title":"BMC Cancer"},{"key":"2214_CR41","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3171\/jns.1996.85.4.0642","volume":"85","author":"G Fries","year":"1996","unstructured":"Fries G, Perneczky A, Kempski O (1996) Glioblastoma-associated circulating monocytes and the release of epidermal growth factor. J Neurosurg 85:642\u2013647","journal-title":"J Neurosurg"},{"key":"2214_CR42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jneuroim.2010.03.011","volume":"223","author":"W Jia","year":"2010","unstructured":"Jia W, Jackson-Cook C, Graf MR (2010) Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma + vaccination model. J Neuroimmunol 223:20\u201330","journal-title":"J Neuroimmunol"},{"key":"2214_CR43","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1158\/1078-0432.CCR-12-1940","volume":"19","author":"M Prosniak","year":"2013","unstructured":"Prosniak M, Harshyne LA, Andrews DW, Kenyon LC, Bedelbaeva K, Apanasovich TV, Heber-Katz E, Curtis MT, Cotzia P, Hooper DC (2013) Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clin Cancer Res 19:3776\u20133786","journal-title":"Clin Cancer Res"},{"key":"2214_CR44","doi-asserted-by":"publisher","first-page":"e85841","DOI":"10.1172\/jci.insight.85841","volume":"1","author":"K Gabrusiewicz","year":"2016","unstructured":"Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, Thomas G, Zhou S, Wang Q, Elakkad A, Liebelt BD, Yaghi NK, Ezhilarasan R, Huang N, Weinberg JS, Prabhu SS, Rao G, Sawaya R, Langford LA, Bruner JM, Fuller GN, Bar-Or A, Li W, Colen RR, Curran MA, Bhat KP, Antel JP, Cooper LJ, Sulman EP, Heimberger AB (2016) Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight 1:e85841","journal-title":"JCI Insight"},{"key":"2214_CR45","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1182\/blood-2013-04-495424","volume":"122","author":"G Nizzoli","year":"2013","unstructured":"Nizzoli G, Krietsch J, Weick A, Steinfelder S, Facciotti F, Gruarin P, Bianco A, Steckel B, Moro M, Crosti M, Romagnani C, Stolzel K, Torretta S, Pignataro L, Scheibenbogen C, Neddermann P, De Francesco R, Abrignani S, Geginat J (2013) Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood 122:932\u2013942","journal-title":"Blood"},{"key":"2214_CR46","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/neuonc\/nov107","volume":"18","author":"LA Harshyne","year":"2016","unstructured":"Harshyne LA, Nasca BJ, Kenyon LC, Andrews DW, Hooper DC (2016) Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients. Neuro Oncol 18:206\u2013215","journal-title":"Neuro Oncol"},{"key":"2214_CR47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1846","author":"K Woroniecka","year":"2018","unstructured":"Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, Elsamadicy AA, Cui X, Koyama S, Jackson C, Hansen LJ, Johanns TM, Sanchez-Perez L, Chandramohan V, Yu YA, Bigner DD, Giles A, Healy P, Dranoff G, Weinhold KJ, Dunn GP, Fecci PE (2018) T-cell exhaustion Ssignatures vary with tumor type and are severe in glioblastoma. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1846","journal-title":"Clin Cancer Res"},{"key":"2214_CR48","first-page":"8408","volume":"63","author":"IF Hermans","year":"2003","unstructured":"Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V (2003) Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 63:8408\u20138413","journal-title":"Cancer Res"},{"key":"2214_CR49","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1182\/blood-2008-01-135319","volume":"112","author":"MA Morse","year":"2008","unstructured":"Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, Clay TM (2008) Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112:610\u2013618","journal-title":"Blood"},{"key":"2214_CR50","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","volume":"105","author":"ME Lutsiak","year":"2005","unstructured":"Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H (2005) Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862\u20132868","journal-title":"Blood"},{"key":"2214_CR51","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00262-009-0734-3","volume":"59","author":"V Radojcic","year":"2010","unstructured":"Radojcic V, Bezak KB, Skarica M, Pletneva MA, Yoshimura K, Schulick RD, Luznik L (2010) Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother 59:137\u2013148","journal-title":"Cancer Immunol Immunother"},{"key":"2214_CR52","doi-asserted-by":"publisher","first-page":"952469","DOI":"10.1155\/2013\/952469","volume":"2013","author":"W Maes","year":"2013","unstructured":"Maes W, Verschuere T, Van Hoylandt A, Boon L, Van Gool S (2013) Depletion of regulatory T cells in a mouse experimental glioma model through anti-CD25 treatment results in the infiltration of non-immunosuppressive myeloid cells in the brain. Clin Dev Immunol 2013:952469","journal-title":"Clin Dev Immunol"},{"key":"2214_CR53","doi-asserted-by":"publisher","first-page":"4927","DOI":"10.4049\/jimmunol.171.9.4927","volume":"171","author":"CJ Wheeler","year":"2003","unstructured":"Wheeler CJ, Black KL, Liu G, Ying H, Yu JS, Zhang W, Lee PK (2003) Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol 171:4927\u20134933","journal-title":"J Immunol"},{"key":"2214_CR54","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4049\/jimmunol.147.2.398","volume":"147","author":"BM Chan","year":"1991","unstructured":"Chan BM, Wong JG, Rao A, Hemler ME (1991) T cell receptor-dependent, antigen-specific stimulation of a murine T cell clone induces a transient, VLA protein-mediated binding to extracellular matrix. J Immunol 147:398\u2013404","journal-title":"J Immunol"},{"key":"2214_CR55","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.immuni.2004.12.008","volume":"22","author":"T Calzascia","year":"2005","unstructured":"Calzascia T, Masson F, Di Berardino-Besson W, Contassot E, Wilmotte R, Aurrand-Lions M, Ruegg C, Dietrich PY, Walker PR (2005) Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 22:175\u2013184","journal-title":"Immunity"},{"key":"2214_CR56","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1097\/CJI.0b013e3181acec1e","volume":"32","author":"K Sasaki","year":"2009","unstructured":"Sasaki K, Pardee AD, Qu Y, Zhao X, Ueda R, Kohanbash G, Bailey LM, Okada H, Muthuswamy R, Kalinski P, Basse PH, Falo LD, Storkus WJ (2009) IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors. J Immunother 32:793\u2013802","journal-title":"J Immunother"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2214-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2214-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2214-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:16:46Z","timestamp":1693786606000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2214-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,27]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["2214"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2214-0","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,27]]},"assertion":[{"value":"16 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The biomarker study has been reviewed and approved bythe Ethikkommission bei der Medizinischen Fakult\u00e4t der Universit\u00e4t W\u00fcrzburg(# 135\/09). All patients were treated after informed consent, in case of minors by their guardians. The clinical trialHIT-HGG Rez Immunovac trial(Eudra-CT: 2013-000419-26) is performed in accordance with the declaration of Helsinki. It was reviewed and approved by theEthikkommission bei der Medizinischen Fakult\u00e4t der Universit\u00e4t W\u00fcrzburg(# 175\/16_ff), and is currently recruiting patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and ethical standards"}},{"value":"All participants of the biomarker study (#135\/09) as well as the patients treated within the pilot phase of the HIT-HGG Rez Immunovac trial (#175\/16_ff) were only sampled or treated after receiving informed consent from the patients or their guardians.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}